Ionis Pharmaceuticals/$IONS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Ticker
$IONS
Sector
Primary listing
Employees
1,069
Headquarters
Website
IONS Metrics
BasicAdvanced
$11B
-
-$1.72
0.25
-
Price and volume
Market cap
$11B
Beta
0.25
52-week high
$69.25
52-week low
$23.95
Average daily volume
3M
Financial strength
Current ratio
2.872
Quick ratio
2.612
Long term debt to equity
210.601
Total debt to equity
314.062
Interest coverage (TTM)
-2.67%
Profitability
EBITDA (TTM)
-255.171
Gross margin (TTM)
5.30%
Net profit margin (TTM)
-28.43%
Operating margin (TTM)
-28.23%
Effective tax rate (TTM)
2.21%
Revenue per employee (TTM)
$880,000
Management effectiveness
Return on assets (TTM)
-5.87%
Return on equity (TTM)
-59.91%
Valuation
Price to revenue (TTM)
11.428
Price to book
17.42
Price to tangible book (TTM)
17.43
Price to free cash flow (TTM)
-38.193
Free cash flow yield (TTM)
-2.62%
Free cash flow per share (TTM)
-1.811
Growth
Revenue change (TTM)
16.05%
Earnings per share change (TTM)
-31.83%
3-year revenue growth (CAGR)
3.60%
10-year revenue growth (CAGR)
11.71%
3-year earnings per share growth (CAGR)
105.41%
10-year earnings per share growth (CAGR)
24.66%
What the Analysts think about IONS
Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
Bulls say / Bears say
FDA approval of Dawnzera diversifies Ionis’ commercial portfolio and is forecast to achieve peak annual sales of $509 million by 2032, bolstering revenue streams (Reuters).
Patent lawsuit against Arrowhead strengthens protection of Tryngolza’s IP, potentially preserving exclusivity for a drug with roughly $2.5 billion in peak sales (Reuters).
Following Tryngolza trial data, Ionis’ shares surged 34%, reflecting strong investor confidence in its rare-disease therapy franchise (Reuters).
Ongoing patent litigation against Arrowhead could divert resources and risk injunctions, potentially delaying market expansion of rival FCS treatments (Reuters).
Dawnzera enters a competitive HAE prophylaxis market alongside established therapies like Takhzyro (87% reduction) and Haegarda, which may limit its uptake despite 81% efficacy (Reuters).
Ionis trades at elevated valuation metrics, with a price-to-sales ratio above 10x and price-to-book exceeding 16x, suggesting potential downside from valuation normalization (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
IONS Financial Performance
Revenues and expenses
IONS Earnings Performance
Company profitability
IONS News
AllArticlesVideos
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
Benzinga2 weeks ago
Ionis' brain disorder drug shows promise in clinical trial
Reuters2 weeks ago
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals (IONS) has a market cap of $11B as of October 04, 2025.
What is the P/E ratio for Ionis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of October 04, 2025.
Does Ionis Pharmaceuticals stock pay dividends?
No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of October 04, 2025.
When is the next Ionis Pharmaceuticals dividend payment date?
Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.
What is the beta indicator for Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.